D
David J. Brooks
Researcher at University College London
Publications - 1209
Citations - 107074
David J. Brooks is an academic researcher from University College London. The author has contributed to research in topics: Parkinson's disease & Galaxy. The author has an hindex of 152, co-authored 1056 publications receiving 94335 citations. Previous affiliations of David J. Brooks include University of Surrey & Imperial College London.
Papers
More filters
Journal ArticleDOI
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more
TL;DR: Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction.
Journal ArticleDOI
Second consensus statement on the diagnosis of multiple system atrophy
Sid Gilman,Gregor K. Wenning,Phillip A. Low,David J. Brooks,C. J. Mathias,John Q. Trojanowski,Nicholas W. Wood,Carlo Colosimo,Alexandra Durr,Clare J. Fowler,Horacio Kaufmann,Thomas Klockgether,AJ Lees,Werner Poewe,Niall Quinn,Tamas Revesz,David Robertson,Paola Sandroni,Klaus Seppi,Marie Vidailhet +19 more
TL;DR: New criteria for diagnosis of multiple system atrophy have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.
Journal ArticleDOI
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
TL;DR: Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.
Journal ArticleDOI
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Steven S. Gill,Nikunj K. Patel,Gary Hotton,Karen O’Sullivan,Renée McCarter,Martin Bunnage,David J. Brooks,Clive N. Svendsen,Peter Heywood +8 more
TL;DR: Positron emission tomography scans of [18F]dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, suggesting a direct effect of GDNF on dopamine function, and warrants careful examination ofGDNF as a treatment for Parkinson disease.
Journal ArticleDOI
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.